Opinion|Videos|March 6, 2025
Exploring Third-Line Options in HER2+ mBC: Janet’s Case & Key Trial Insights from HER2CLIMB and EMILIA
Dr O’Shaughnessy leads a panel of medical experts in a discussion around a patient case surrounding findings from HER2CLIMB and EMILIA clinical trials.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please explore key clinical trial data findings, emphasizing perspectives around clinical safety and efficacy.
Advertisement
Related to this article
The phase 3 NRG-GI003 trial showed no overall survival benefit with proton therapy over photon therapy in patients with advanced hepatocellular carcinoma.
In a secondary analysis of the DEPROMP trial, 94.8% of biopsy-naive men had no AEs immediately after multimodal MRI- and PSMA PET/CT–guided prostate biopsy.
C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.
Ethan B. Ludmir, MD, explains why advanced radiation techniques like protons fit nonoperative cholangiocarcinoma better than the preoperative setting.
10-year CHN HYPOPMRT data show 3-week postmastectomy RT with nodal irradiation maintains locoregional control without added severe late toxicity.
Ayal Aizer, MD, MHS, explains why fractionated SRS outperformed single-fraction SRS for surgical bed control in Alliance A071801.
Andy Liao, MD, discusses KRAS-targeted strategies, molecular profiling, multidisciplinary care, and FGFR2 inhibitor sequencing in cholangiocarcinoma.
“To me, the biggest differentiator might be how the patient wants to experience care,” said Krish Patel, MD, on treatment options for patients with lymphoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Distal Extrahepatic Cholangiocarcinoma May Gain From Neoadjuvant Radiation
2
Hydrogel Spacer Receives FDA 510(k) Clearance for Prostate Cancer Radiotherapy
3
The Value of Testing in The Expanding EGFR Exon 20 Insertion Landscape
4
PDS0101/Pembrolizumab Yields 39.3-Month Median OS in HPV16-Positive HNSCC
5